Navigation Links
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Date:9/24/2009

ntains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 24, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, e
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
2. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
3. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
4. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
5. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
6. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
7. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
8. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
9. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 1, 2014 The global high content screening ... the ,Threat of Obsolescence, wherein technologies as well as ... and biotechnology companies as well as academic and government ... as a powerful research tool in drug discovery. The ... in the high content screening market. In high content ...
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, Inc. ... patented and proprietary technology used to develop and ... bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today ... from Abengoa Bioenergy for commercial scale production of ... into ethanol, developed under Abengoa,s license agreement with ...
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014 /PRNewswire/ ... cell-free molecular diagnostics, announced today that Eli ... Sloan Kettering Cancer Center (MSK), presented clinical data ... Trovagene,s precision cancer monitoring platform for the determination ... from a liquid biopsy.  The results were presented ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
(Date:10/1/2014)... published today in the Journal of the American ... 50 years with moderate or severe chronic knee pain, ... the University of Melbourne randomly assigned 282 patients (50 ... acupuncture or sham or pretend laser treatment. , ... acupuncturists blinded to laser and sham (inactive) laser acupuncture. ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
(Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2
... ... product development. , ... Toronto, ON (Vocus) March 29, 2010 -- Therapure Biopharma Inc. today announced a fill/finish ... Under the terms of the agreement, Therapure will provide custom fill/finish services for a ...
... ... nonprofit organization that engages hundreds of thousands of students into humanitarian ... collaborative management of tasks and workflow. Absolute’s Chief Operating Officer reports ... operations transparency, thanks to Wrike’s unique project collaboration features. , ...
... enrolled in therapeutic clinical research trials shows that they don,t ... participation, nor do they feel they are genuinely involved in ... Yoram Unguru, M.D., an associate faculty member at the Johns ... 29 in the journal Pediatrics . While an ...
... combination destroys precancerous colon polyps with no effect on normal ... cancer, a team of scientists at The University of Texas ... edition of the journal Nature . The regimen, ... cancer tissue in the lab, appears to address a problem ...
... rats, the more fattening foods they ate, the more they wanted ... they,d like to eat less but feel almost powerless to stop ... too true. , The theory stems from a study in rats. ... of bacon, pound cake, candy bars and other junk food, the ...
... Unethical job ... wage jobs in Canada. Sometimes these carers do not even have a job when they ... one Vancouver-based business owner says problems could persist. , ... (PRWEB) March 28, 2010 -- New federal legislation coming into force ...
Cached Medicine News:Health News:Therapure Biopharma Inc. signs fill/finish contract with Kane Biotech Inc. 2Health News:COO Becomes 75% More Effective in Tracking Delegated Tasks 2Health News:COO Becomes 75% More Effective in Tracking Delegated Tasks 3Health News:Childhood cancer patients enrolled in clinical trials need clearer communication about their role 2Health News:Childhood cancer patients enrolled in clinical trials need clearer communication about their role 3Health News:Paired drugs kill precancerous colon polyps, spare normal tissue 2Health News:Paired drugs kill precancerous colon polyps, spare normal tissue 3Health News:Junk Food 'Addiction' May Be Real 2Health News:Junk Food 'Addiction' May Be Real 3Health News:Exploitation of Overseas Nannies and Caregivers Could Continue Despite New Canadian Immigration Laws 2Health News:Exploitation of Overseas Nannies and Caregivers Could Continue Despite New Canadian Immigration Laws 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: